ClinicalTrials.gg
CompletedNCT05435677Updated Mar 21, 2025

A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together

A Phase 1 interventional study of IcoSema and insulin icodec in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
26th of 27
20 · median 84
Started
2022
with 1 other
Phase 1
13 of 27
none open now
Registered
20th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 26th largest by enrollment, is one of 2 that started in 2022, is one of 13 in phase 1, and was the 20th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will look at a new medicine, called IcoSema, for treatment of type 2 diabetes.

IcoSema is a combination of a new insulin, called insulin icodec, and a GLP-1 receptor analogue, called semaglutide.

Insulin icodec is a possible new medicine. That means that the medicine has not yet been approved by the authorities. Semaglutide is a medicine already approved by the authorities in the EU, USA, China and Japan.

The study will look at the way insulin icodec and semaglutide reach and stay in participants blood after injection when given together as IcoSema or alone as insulin icodec and semaglutide.

Participants will get each of the 3 medicines (IcoSema, insulin icodec and semaglutide) at 3 different timepoints:

The order in which participants get them is decided by chance. Participants will get the 3 medicines as an injection under the skin in the thigh. The injections will be done by study staff. The time between injections is 6 to 9 weeks.

The study will last for about 19 to 26 weeks. Participants will have 31 or 32 visits to the clinic. 3 of the visits will be in-house visits, meaning that participants will stay at the clinic for 5 or 6 days (4 or 5 nights).

Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese male or female
  • Aged 18-64 years (both inclusive) at the time of signing
  • Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening
  • between 18.5 and 34.9 kg/m\^2 (both inclusive)
  • Body weight greater than or equal to 50 kg
  • (glycated haemoglobin) below or equal to 9.0% (75 mmol/mol)
  • Insulin naïve. However, short-term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes
  • Stable daily dose(s) including any of the following anti-diabetic drug(s)/regimen within 45 days prior to the day of screening:

    • Any metformin formulation
    • DPP-4 (dipeptidyl peptidase-4) inhibitors (participants are not allowed to participate in the study if they are treated with DPP-4 inhibitors as monotherapy)
    • SGLT2 (sodium-glucose linked transporter 2) inhibitors
    • Alpha-glucosidase inhibitors
    • Oral combination products (for the allowed individual oral antidiabetic drugs)

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to trial product(s) or related products
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using highly effective method
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days prior to the day of screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Sequence 1

    All participants will get each of the 3 medicines at 3 different timepoints IcoSema - insulin icodec - semaglutide, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.

    Drug: IcoSema · Drug: insulin icodec · Drug: semaglutide

  • Experimental
    Sequence 2

    All participants will get each of the 3 medicines at 3 different timepoints IcoSema- semaglutide . insulin icodec, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.

    Drug: IcoSema · Drug: insulin icodec · Drug: semaglutide

  • Experimental
    Sequence 3

    All participants will get each of the 3 medicines at 3 different timepoints insulin icodec- IcoSema- semaglutide, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.

    Drug: IcoSema · Drug: insulin icodec · Drug: semaglutide

  • Experimental
    Sequence 4

    All participants will get each of the 3 medicines at 3 different timepoints insulin icodec- semaglutide - IcoSema separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.

    Drug: IcoSema · Drug: insulin icodec · Drug: semaglutide

  • Experimental
    Sequence 5

    All participants will get each of the 3 medicines at 3 different timepoints semaglutide - IcoSema - insulin icodec, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.

    Drug: IcoSema · Drug: insulin icodec · Drug: semaglutide

  • Experimental
    Sequence 6

    All participants will get each of the 3 medicines at 3 different timepoints semaglutide - insulin icodec - IcoSema, separated by a 1-4-week wash-out period. The study will last for about 19 to 26 weeks.

    Drug: IcoSema · Drug: insulin icodec · Drug: semaglutide

Interventions

  • DrugIcoSema

    Drug pages: Insulin icodec · Semaglutide

    One single dose of IcoSema administered subcutaneously, S.c. into the left thigh

  • One single dose of insulin icodec administered subcutaneously, S.c. into the left thigh

  • One single dose of semaglutide administered subcutaneously, S.c. into the left thigh

06

What researchers measure

Primary outcomes

  1. AUCIco,0-tz:Area under the serum insulin icodec concentration-time curve after a single dose

    Measured in hours\*pmol/L

    Time frame: From 0 hours to tz hours after IMP administration (day 1) where tz is the time of the last quantifiable concentration

  2. Dose-normalised AUCSema,0-tz: Area under the plasma semaglutide concentration-time curve after a single dose divided by dose

    Measured in (hours\*nmol/L)/mg

    Time frame: From 0 hours to tz hours after IMP administration (day 1) where tz is the time of the last quantifiable concentration

Secondary outcomes

  1. AUCIco,0-inf: Area under the serum insulin icodec concentration-time curve after a single dose

    Measured in hours\*pmol/L

    Time frame: From 0 hours to infinity after IMP administration (day 1)

  2. Cmax,Ico: Maximum observed serum insulin icodec concentration after a single dose

    Measured in pmol/L

    Time frame: From 0 hours until last measurement time after IMP administration (day 1)

  3. tmax,Ico: Time to maximum observed serum insulin icodec concentration after a single dose

    Measured in hours

    Time frame: From 0 hours until last measurement time after IMP administration (day 1)

  4. t1/2,Ico: Terminal half-life for insulin icodec after a single dose

    Measured in hours

    Time frame: Terminal part of the serum insulin icodec concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after IMP administration (day 1)

  5. Dose-normalised AUCSema,0-inf: Area under the plasma semaglutide concentration-time curve after a single dose divided by dose

    Measured in (hours\*nmol/L)/mg

    Time frame: From 0 hours to infinity after IMP administration (day 1)

  6. Dose-normalised Cmax,Sema: Maximum observed plasma semaglutide concentration after a single dose divided by dose

    Measured in (nmol/L)/mg

    Time frame: From 0 hours until last measurement time after IMP administration (day 1)

  7. tmax,Sema: Time to maximum observed plasma semaglutide concentration after a single dose

    Measured in hours

    Time frame: From 0 hours until last measurement time after IMP administration (day 1)

  8. t1/2,Sema: Terminal half-life for semaglutide after a single dose

    Measured in hours

    Time frame: Terminal part of the plasma semaglutide concentration-time curve where the curve is well approximated by a straight line on logarithmic scale after IMP administration (day 1)

  9. Adverse events

    Number of events

    Time frame: From IMP administration (day 1) to end of follow-up for each treatment period (day 36)

07

Study locations

1 site
  • Peking University Third Hospital, Northern branch-Phase I
    Beijing, Beijing 100089, China
08

References and documents

Individual participant data

Plan to share: Yes — "According to the Novo Nordisk disclosure commitment on novonordisk-trials.com"

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Apr 2023, 10 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 10 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2022
First posted
Jun 28, 2022
StartActual
Jun 22, 2022
Primary completionActual
Apr 25, 2023
CompletionActual
Apr 25, 2023
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05435677
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 28, 2022
Start date
Jun 22, 2022
Primary completion
Apr 25, 2023
Completion
Apr 25, 2023
Last update
Mar 21, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion